Humira Approved for Treating Hidradenitis Suppurativa
September 10, 2015 – The U.S. Food and Drug Administration (FDA) approved Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS), a follow up to its earlier designation of Humira as an orphan drug for HS. HS is a chronic inflammatory skin disease characterized by swollen, painful lesions under the breasts, between the buttocks, and around the armpits and groin. Humira, manufactured by AbbVie, is the first FDA-approved treatment for HS and was previously indicated to treat eight conditions in adults and children including polyarticular juvenile idiopathic arthritis, rheumatoid arthritis and Crohn’s disease. Alternate treatments for HS include surgery to remove affected skin and antibiotics to treat infections.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.